Alimera Sciences, Inc. (ALIM)
USD 5.54
(-0.18%)
USD 5.54
(-0.18%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 62.64 Million USD | 8.39% |
| 2022 | 57.79 Million USD | 10.71% |
| 2021 | 52.2 Million USD | 17.62% |
| 2020 | 44.38 Million USD | -15.61% |
| 2019 | 52.59 Million USD | 1.21% |
| 2018 | 51.96 Million USD | 0.36% |
| 2017 | 51.77 Million USD | -13.47% |
| 2016 | 59.83 Million USD | 0.27% |
| 2015 | 59.67 Million USD | 49.46% |
| 2014 | 39.92 Million USD | 16.03% |
| 2013 | 34.41 Million USD | 56.15% |
| 2012 | 22.03 Million USD | 2.95% |
| 2011 | 21.4 Million USD | -3.01% |
| 2010 | 22.07 Million USD | 14.86% |
| 2009 | 19.21 Million USD | -61.63% |
| 2008 | 50.08 Million USD | 300.14% |
| 2007 | 12.51 Million USD | 20.58% |
| 2006 | 10.38 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 18.69 Million USD | 1.32% |
| 2024 Q2 | 20.13 Million USD | 7.7% |
| 2023 Q4 | 18.45 Million USD | 15.39% |
| 2023 Q3 | 15.99 Million USD | -2.0% |
| 2023 FY | 62.64 Million USD | 8.39% |
| 2023 Q1 | 14.82 Million USD | 5.77% |
| 2023 Q2 | 16.32 Million USD | 10.13% |
| 2022 Q2 | 14.41 Million USD | 0.33% |
| 2022 Q4 | 14.01 Million USD | -6.61% |
| 2022 Q1 | 14.36 Million USD | -2.58% |
| 2022 Q3 | 15 Million USD | 4.1% |
| 2022 FY | 57.79 Million USD | 10.71% |
| 2021 Q4 | 14.74 Million USD | 18.09% |
| 2021 Q2 | 12.88 Million USD | 6.66% |
| 2021 Q1 | 12.08 Million USD | 4.07% |
| 2021 FY | 52.2 Million USD | 17.62% |
| 2021 Q3 | 12.48 Million USD | -3.11% |
| 2020 Q1 | 12.39 Million USD | -9.22% |
| 2020 Q2 | 9.85 Million USD | -20.48% |
| 2020 Q3 | 10.52 Million USD | 6.87% |
| 2020 Q4 | 11.6 Million USD | 10.26% |
| 2020 FY | 44.38 Million USD | -15.61% |
| 2019 Q2 | 13.27 Million USD | 4.62% |
| 2019 Q1 | 12.68 Million USD | -7.52% |
| 2019 Q4 | 13.64 Million USD | 5.09% |
| 2019 FY | 52.59 Million USD | 1.21% |
| 2019 Q3 | 12.98 Million USD | -2.14% |
| 2018 Q3 | 12.36 Million USD | -1.71% |
| 2018 FY | 51.96 Million USD | 0.36% |
| 2018 Q1 | 13.29 Million USD | -3.92% |
| 2018 Q2 | 12.58 Million USD | -5.36% |
| 2018 Q4 | 13.71 Million USD | 10.92% |
| 2017 FY | 51.77 Million USD | -13.47% |
| 2017 Q4 | 13.83 Million USD | -10.27% |
| 2017 Q3 | 15.42 Million USD | 40.48% |
| 2017 Q2 | 10.97 Million USD | -4.9% |
| 2017 Q1 | 11.54 Million USD | -23.65% |
| 2016 Q4 | 15.11 Million USD | 0.42% |
| 2016 FY | 59.83 Million USD | 0.27% |
| 2016 Q1 | 14.21 Million USD | -5.97% |
| 2016 Q3 | 15.05 Million USD | -2.56% |
| 2016 Q2 | 15.45 Million USD | 8.7% |
| 2015 Q4 | 15.11 Million USD | 2.75% |
| 2015 FY | 59.67 Million USD | 49.46% |
| 2015 Q1 | 14.64 Million USD | 16.9% |
| 2015 Q2 | 15.2 Million USD | 3.76% |
| 2015 Q3 | 14.71 Million USD | -3.22% |
| 2014 Q2 | 7.77 Million USD | -13.3% |
| 2014 Q4 | 12.53 Million USD | 17.54% |
| 2014 Q3 | 10.66 Million USD | 37.17% |
| 2014 Q1 | 8.96 Million USD | 8.93% |
| 2014 FY | 39.92 Million USD | 16.03% |
| 2013 FY | 34.41 Million USD | 56.15% |
| 2013 Q2 | 9.5 Million USD | 15.15% |
| 2013 Q3 | 8.41 Million USD | -11.47% |
| 2013 Q4 | 8.22 Million USD | -2.23% |
| 2013 Q1 | 8.25 Million USD | 0.55% |
| 2012 Q2 | 4.49 Million USD | 8.82% |
| 2012 Q1 | 4.12 Million USD | -28.95% |
| 2012 Q4 | 8.21 Million USD | 57.66% |
| 2012 FY | 22.03 Million USD | 2.95% |
| 2012 Q3 | 5.2 Million USD | 15.94% |
| 2011 FY | 21.4 Million USD | -3.01% |
| 2011 Q3 | 6.25 Million USD | 27.02% |
| 2011 Q2 | 4.92 Million USD | 11.6% |
| 2011 Q1 | 4.41 Million USD | -26.96% |
| 2011 Q4 | 5.81 Million USD | -7.14% |
| 2010 Q2 | 5.69 Million USD | 35.03% |
| 2010 Q1 | 4.21 Million USD | -2.97% |
| 2010 Q4 | 6.04 Million USD | -1.24% |
| 2010 FY | 22.07 Million USD | 14.86% |
| 2010 Q3 | 6.11 Million USD | 7.48% |
| 2009 Q3 | 4.63 Million USD | -2.38% |
| 2009 Q4 | 4.34 Million USD | -6.24% |
| 2009 FY | 19.21 Million USD | -61.63% |
| 2009 Q1 | 5.49 Million USD | -18.77% |
| 2009 Q2 | 4.74 Million USD | -13.53% |
| 2008 Q1 | 33.52 Million USD | 0.0% |
| 2008 FY | 50.08 Million USD | 300.14% |
| 2008 Q3 | 5.26 Million USD | 16.0% |
| 2008 Q2 | 4.53 Million USD | -86.47% |
| 2008 Q4 | 6.75 Million USD | 28.42% |
| 2007 FY | 12.51 Million USD | 20.58% |
| 2007 Q1 | 2.97 Million USD | 0.0% |
| 2007 Q2 | 3.12 Million USD | 5.18% |
| 2006 FY | 10.38 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 60.655% |
| Embecta Corp. | 528.4 Million USD | 88.145% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 68.038% |
| Dynavax Technologies Corporation | 219.14 Million USD | 71.416% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 76.961% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 80.807% |
| PainReform Ltd. | 9.58 Million USD | -553.6% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -39.655% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -377.284% |
| SCYNEXIS, Inc. | 51.84 Million USD | -20.817% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -1940.963% |
| Cosmos Health Inc. | 26.18 Million USD | -139.263% |
| Journey Medical Corporation | 54.59 Million USD | -14.74% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -377.284% |
| Safety Shot Inc | 12.1 Million USD | -417.28% |
| Alpha Teknova, Inc. | 45.85 Million USD | -36.595% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 89.383% |
| Bright Green Corporation | 8.25 Million USD | -659.021% |
| Procaps Group, S.A. | 199.47 Million USD | 68.597% |
| Theratechnologies Inc. | 72.75 Million USD | 13.903% |
| Harrow Health, Inc. | 89.97 Million USD | 30.378% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -563.148% |
| Biofrontera Inc. | 39.95 Million USD | -56.763% |
| DURECT Corporation | 43.71 Million USD | -43.294% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 88.159% |
| Cronos Group Inc. | 96.7 Million USD | 35.227% |
| OptiNose, Inc. | 85.1 Million USD | 26.393% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 73.014% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -59.99% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 755.172% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 80.059% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -543.737% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -45.539% |
| Radius Health, Inc. | 265.92 Million USD | 76.444% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -352.546% |
| ProPhase Labs, Inc. | 37.85 Million USD | -65.489% |
| Phibro Animal Health Corporation | 260.29 Million USD | 75.935% |
| Procaps Group S.A. | 187.24 Million USD | 66.546% |
| Alvotech | 285.43 Million USD | 78.054% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -537.567% |
| Viatris Inc. | 5.96 Billion USD | 98.95% |
| Rockwell Medical, Inc. | 15.37 Million USD | -307.448% |
| Aytu BioPharma, Inc. | 59.84 Million USD | -4.681% |
| SIGA Technologies, Inc. | 22.04 Million USD | -184.176% |
| Tilray Brands, Inc. | 251.35 Million USD | 75.079% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | -27.74% |
| Shineco, Inc. | 17.94 Million USD | -249.013% |
| PetIQ, Inc. | 192.72 Million USD | 67.497% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -1469.502% |
| Incannex Healthcare Limited | 30.05 Million USD | -108.435% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 96.076% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -8115.299% |
| Assertio Holdings, Inc. | 368.58 Million USD | 83.005% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -964.315% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -251.747% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -195.909% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -197.694% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 62.028% |
| Hempacco Co., Inc. | 7.59 Million USD | -724.609% |
| Talphera, Inc. | 11.99 Million USD | -422.269% |
| Alvotech | 285.43 Million USD | 78.054% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 55.483% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 81.838% |
| Currenc Group, Inc. | 24 Million USD | -160.981% |
| Kamada Ltd. | 45.42 Million USD | -37.897% |
| Indivior PLC | 911 Million USD | 93.124% |
| Evoke Pharma, Inc. | 12.4 Million USD | -404.777% |
| Flora Growth Corp. | 10.57 Million USD | -492.126% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -197.694% |
| Evolus, Inc. | 189.75 Million USD | 66.989% |
| HUTCHMED (China) Limited | 436.23 Million USD | 85.64% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 59.359% |
| Akanda Corp. | 3.48 Million USD | -1698.216% |